U.S. research roundup: Affiliated Managers Group, Goldman Sachs, Vaxcyte
GS•Analysts raised Affiliated Managers Group’s price target to $456 from $441 and cut Goldman Sachs’ to $1,124 from $1,299. Vaxcyte’s target rose to $122 from $110; targets were also raised for Regeneron and Charles Schwab.
1. Analyst target changes
Jefferies raised its price target for Affiliated Managers Group to $456 from $441 and cut its target for Goldman Sachs to $1,124 from $1,299. Needham raised its target for Vaxcyte to $122 from $110, while JP Morgan raised Regeneron’s target to $950 from $900 and Jefferies raised Charles Schwab’s to $131 from $126.
2. Other research actions
The roundup lists analyst rating and price-target changes across many other U.S.-listed companies. Among them, Scotiabank raised AbbVie’s target to $320 from $280, and several firms raised PTC’s target to $205 while revising ratings.
